As might be expected from the first line use of bevacizumab with chemotherapy, there were slightly higher rates of grade 3 or greater adverse events in the bevacizumab arm versus the control arm, with four treatment related

grade 5 events occurring in the bevacizumab arm and three events occurring in the control Inhibitors,research,lifescience,medical arm. The rates of benefit versus adverse events suggest that the continuation of bevacizumab along with second line chemotherapy is appropriate, even when it was a part of the first line treatment regimen. Importantly, the use of aflibercept has only been combined with the FOLFIRI chemotherapy regimen in the second line management of patients with metastatic colorectal cancer. Thus, for patients who have progressed through first line chemotherapy with an irinotecan-containing regimen, there is no evidence for the addition Inhibitors,research,lifescience,medical of aflibercept to an oxaliplatin-containing second line regimen. Should the use of an anti-angiogenic agent be desired in conjunction with an oxaliplatin-based second line chemotherapeutic regimen in metastatic colorectal Inhibitors,research,lifescience,medical cancer following progression on an irinotecan-based primary

regimen, the studies described above http://www.selleckchem.com/products/qnz-evp4593.html demonstrate good evidence for the use of bevacizumab, regardless of whether or not it was a part of the primary therapeutic regimen (18,20). Thus far, there is no evidence for superior benefit or tolerance of either bevacizumab or aflibercept when added Inhibitors,research,lifescience,medical to chemotherapy in the second line management of metastatic colorectal

cancer. Regardless of the first line chemotherapy used and of the use of bevacizumab first line, there is good evidence for the inclusion of an anti-angiogenic agent in conjunction with second line chemotherapy in this patient population, with the specific selection of the anti-angiogenic agent to be dictated by the chemotherapeutic regimen to be used and the potential Inhibitors,research,lifescience,medical side-effects associated with the different anti-angiogenic agents. Anti-angiogenesis therapy in refractory metastatic colorectal cancer As the role for the various anti-angiogenesis agents has been explored in a variety of settings, bevacizumab has been evaluated through in an expanded access trial for activity in patients who had progressed through all standard chemotherapy but remained bevacizumab naïve. In this single arm study, patients whose metastatic colorectal cancer was refractory to irinotecan and oxaliplatin containing chemotherapy regimens were treated with a combination of bevacizumab, and leucovorin/5-fluorourical (either as bolus or continuous infusion at the treating physician’s discretion) (21). An important restriction in this trial was that patients could not have received bevacizumab previously. A response rate of 4% resulted, with side effect rates similar to other trials.